Tofacitinib in Juvenile Idiopathic Arthritis

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Juvenile Idiopathic Arthritis (JIA) Arthritis Arthritis, Juvenile Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Sant Joan de Déu Barcelona, Barcelona, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.

Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.

Age under 18 years at the time of the treatment indication with tofacitinib.

Exclusion criteria

Participants diagnosed with any of the following conditions:

Reactive arthritis

Arthritis associated with inflammatory bowel disease

Arthritis associated with another autoimmune disease

Treatment and study plan

tofacitinib

Drug

Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).

Primary outcomes

JADAS-10

Time frame: Baseline and 12 months

Change in the Juvenile Arthritis Disease Activity Score (JADAS-10) score at 12 months of treatment with tofacitinib. Range score: 0 to 10, the less score the better

Study contacts

Contact information is provided by the study sponsor or research team.

Noemí Casaponsa

CONTACT

[email protected]

+34938960025 ext. 43197

Sponsors and collaborators

Lead sponsor

Consorci Sanitari de l'Alt Penedès i Garraf

Other

Registry information

Official study title

Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Oct 8, 2025
Registry last updated: Nov 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting